This page shows the latest Quad news and features for those working in and with pharma, biotech and healthcare.
HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad product (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are expected to be
Quad (a combination of the three drugs and tenofovir).
as a combination pill to be called Quad.
Gilead is studying the use of elvitegravir as part of a separate investigational fixed-dose, single-tablet "Quad" regimen. ... Quad pill," said Dr Norbert Bischofberger, executive vice president, R&D and chief scientific officer, Gilead Sciences. .
An exciting new four-in-one fixed-dose tablet, known as "Quad", has been developed by Gilead Sciences. ... CROI. These results demonstrated that the Quad regimen exhibited antiretroviral activity comparable to that of Atripla.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...